The research firm benchmarked Fujitsu across strategy effectiveness and execution, noting how the company aligns advanced computing with specific regional demands. Kenny Yeo, ICT Director at Frost & Sullivan, pointed to Fujitsu's grasp of technology maturity and cost considerations as the primary drivers behind the regional adoption of their optimization tools. Central to this performance is the Digital Annealer, which allows enterprises to process high-dimensional datasets without needing specialized quantum hardware.

Peter Grassi, CEO of Fujitsu in Oceania, noted that the technology is already shifting operations in finance and life sciences. In the financial sector, firms are rebalancing portfolios by running hundreds of scenarios in the time previously required for one. Meanwhile, in drug discovery, the tech is accelerating the identification of chemical candidates. Fujitsu supports these deployments through a structured engagement model that includes proof-of-concept initiatives, intended to lower risk for organizations integrating these advanced methods into their current systems.